Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicamentous application of CPE (Conjugated Polyelectrolyte)

A technology of conjugated polyelectrolyte and pharmaceutical carrier, which is applied in or inferior form of protein, conjugated polyelectrolyte as a new therapeutic agent, can solve the problems of no effective treatment means and lack of reliable methods for capturing misfolded proteins

Inactive Publication Date: 2011-01-19
BIOCHROMIX PHARMA
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Also, there is no effective treatment, and immunotherapy, as performed in Alzheimer's disease, holds great promise
However, the lack of reliable methods for capturing misfolded proteins and monitoring both therapy and disease progression is a serious drawback in the treatment of most protein misfolding-associated diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicamentous application of CPE (Conjugated Polyelectrolyte)
  • Medicamentous application of CPE (Conjugated Polyelectrolyte)
  • Medicamentous application of CPE (Conjugated Polyelectrolyte)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0104] Example 1. Capture and detection of PrP-amyloid in solution using conjugated polyelectrolytes protein. Surface Inspection Using Fluorescence Microscopy

[0105] Tubes containing PrP and PrP-amyloid samples, the latter being PrP Sc - or PrP res-like protein. PrP-amyloid was prepared by dialyzing 1 mg / ml recHuPrP90-231 in 3M guanidinium hydrochloride against water. Another experimental protocol was the preparation of PrP-amyloid by shaking in test tubes under conditions of high salt concentration. To this solution containing PrP and PrP-amyloid was added conjugated polyelectrolyte PTAA (10 μg / ml), allowing PTAA to capture, bind and stain PrP-amyloid. The PTAA / PrP-amyloid former is then left to settle to the bottom of the test tube, whereupon it can be easily separated from the sample and, if necessary, detected. Other methods of collecting PTAA / PrP-amyloid are, but not limited to, filtration, centrifugation, capture on hydrophobic surfaces, capture on surfaces wi...

Embodiment 2

[0106] Example 2: Filtration, capture

[0107] Filtration of the polymer-insulin sample was performed in order to separate native and fibrillar insulin and thereby purify the fibril insulin. The samples tested were native insulin and fibril insulin, with or without PTAA. Initially, the concentration of PTAA was 0.5 mg / ml, the concentration of insulin was 2 mg / ml, and the samples contained 10 μl of PTAA + 25 μl of insulin in 1 ml of 20 mM pH 8 phosphate buffer. For all samples, fluorescence measurements were taken before and after filtration, and the filters were turned on for visual inspection. The filter used was 0.22 μm Millex-gu, and 1 ml of each sample was filtered through the filter.

[0108] Fluorescence spectra of PTAA-native insulin (PTAA-ins) and PTAA-fibril insulin (PTAA-fib) before and after filtration through a 0.22 μm filter are shown in Figure 9 middle. Before filtering, the spectra looked as expected. After filtration, it was apparent that samples contai...

Embodiment 3

[0113] Capture and detection of insulin-amyloid in solution using conjugated polyelectrolytes. profit Solution detection with fluorescence measurement

[0114] In test tubes, samples containing native insulin containing 0, 1, 5, 50 and 100% fibrils were mixed with PTAA (0.05 mg / ml, 10 μl) and 965 μl of 20 mM phosphate buffer pH 7.0 (2 mg / ml, 25 μl). Fibrillar insulin is produced by incubating native insulin at pH 2 for 8 hours at 65°C. The samples were centrifuged at 10,000 rpm for 5 minutes, the supernatant was removed, new buffer was added, and the process was repeated once. The PTAA binds fibril insulin and settles to the bottom of the tube under centrifugation. Samples were then measured using a fluorescent microplate reader. Reference samples of PTAA-native insulin and PTAA-fibril insulin without centrifugation were also measured. display the results in Figure 12 middle.

[0115] The PTAA-fibril aggregates settled to the bottom of the tube and they could be ea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a CPE (Conjugated Polyelectrolyte) as a novel therapeutic agent which takes effect by interfering the formation of misfolding, pathological or rogue proteins or capturing the misfolding, pathological or rogue proteins in vivo.

Description

[0001] This application entered China on December 18, 2009. The international filing date is April 18, 2007. The application number is 200780053410.0 (the international application number is PCT / SE2007 / 050253). A divisional application of the application for "Protein in the form of technical field [0002] The present invention relates to the use of conjugated polyelectrolytes for specifically isolating, e.g. capturing misfolded, pathological or rogue forms of proteins, i.e. amyloid forms, optionally under selective conditions , proteins in misfolded or aggregated forms, and proteins that trap abnormal forms that similarly cause aggregation of proteins that do not aggregate in their normal form. The present invention also relates to a one-step method for simultaneously isolating and detecting misfolded, pathological or dysmorphic forms of proteins. A further embodiment of the invention relates to the use of conjugated polyelectrolytes as novel therapeutic agents which act by ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/795A61P25/28A61P31/12A61P3/10A61P25/16A61P25/14A61P9/04
Inventor P·奥斯伯格O·英格纳斯F·安格斯
Owner BIOCHROMIX PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com